On 17th February, 2009, the European Commission followed suit and approved Degarelix drug for use in adult male patients with advanced prostate cancer.
17th Febraayo, 2009, Guddiga Yurub wuxuu raacay dacwad oo wuxuu oggolaaday daawada Degarelix ee loogu talagalay in lagu isticmaalo bukaannada waaweyn ee ragga ah ee qaba kansarka qanjirka 'prostate'.